Understanding the switchbacks: The impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation

Liver Transplantation

Volumn 18, Issue SUPPL.2, 2012, Pages

  Mutimer, David ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b NIHR Birmingham   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CD81 ANTIGEN; CLAUDIN 1; CYCLOSPORIN; HEMOGLOBIN; HEPATITIS C ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR; OCCLUDIN; PEGINTERFERON ALPHA2B; PROTEOHEPARAN SULFATE; RIBAVIRIN; SCAVENGER RECEPTOR BI; TACROLIMUS; TELAPREVIR;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; GENOTYPE; GRAFT INFECTION; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LEUKOCYTE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERONS; LIVER TRANSPLANTATION; MICE; RECURRENCE; RIBAVIRIN;

EID: 84868098273     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23533     Document Type: Article

References (26)

1. Rowe IA, Mutimer DJ,. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ 2011; 343: d6972.
2. Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) [abstract]. J Hepatol 2012; 56 (suppl 2): S4.
3. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS,. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-288.
4. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-212.
5. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
6. Carriõn JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-728.
7. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C,. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
8. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH,. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-915.
9. Iacobellis A, Siciliano M, Annicchiarico BE, Valvano MR, Niro GA, Accadia L, et al. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009; 30: 146-153.
10. Mutimer DJ, Lok A,. Management of HBV- and HCV-induced end stage liver disease. Gut 2012; 61 (suppl 1): i59-i67.
11. Roche B, Samuel D,. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012; 32 (suppl 1): 120-128.
12. Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909-1913.
13. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820.
14. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
15. Charlton M,. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 2011; 54: 3-5.
16. Oo YH, Mutimer DJ,. Rapid recovery of CYP3A4 following protease inhibitors withdrawal in post liver transplant patients. Liver Transpl 2012; 18: 1264-1265.
17. Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience [abstract]. J Hepatol 2012; 56 (suppl 2): S21.
18. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M,. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053-1059.
19. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al.; for Collaborative Antiviral Study Group. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941-949.
20. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006; 12: 1381-1389.
21. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687.
22. Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006; 12: 207-216.
23. Dragun J, Pérez-Del-Pulgar S, Crespo G, Ramírez S, Coto-Llerena M, Mensa L, et al. Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting. Am J Transplant 2011; 11: 767-774.
24. Timpe JM, McKeating JA,. Hepatitis C virus entry: possible targets for therapy. Gut 2008; 57: 1728-1737.
25. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, Leroux-Roels G,. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008; 48: 1761-1768.
26. Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012; 55: 364-372.